The Application of Extracellular Vesicles Mediated miRNAs in Osteoarthritis: Current Knowledge and Perspective
Xiaobin Shang,Yan Fang,Wenqiang Xin,Hongbo You
DOI: https://doi.org/10.2147/JIR.S359887
IF: 4.5
2022-04-22
Journal of Inflammation Research
Abstract:Xiaobin Shang, 1, &ast Yan Fang, 2, &ast Wenqiang Xin, 3 Hongbo You 1 1 Department of Orthopaedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China; 2 Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China; 3 Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 352000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hongbo You, Email Osteoarthritis (OA) is a whole joint disease characterized by synovitis, cartilage destruction, and subchondral bone sclerosis and cyst. Despite decades' study, effective treatment is rare for this chronic disease. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptosis bodies, are nano-sized vesicles with a cargo containing biologically active agents, such as nucleic acids, lipids, and proteins. As a group of short non-coding RNAs, microRNAs (miRNAs) can be delivered by parental cells secreted EVs. Negatively regulate the target mRNAs at the posttranscriptional level and regulate gene expression in recipient cells without modifying gene sequence. Recently, most studies focused on the function of EVs mediated miRNAs in the pathophysiological process of OA. However, all kinds of EVs specific and OA specific factors might influence the administration of EVs-miRNAs, especially the precise quantitative management. As a result, the flourishing of current research about EVs in the laboratory might not promote the relevant clinical transformation in OA treatment. In this review, we reviewed the present application of EVs-miRNAs in the therapeutic of OA and further analyzed the potential factors that might influence its application. Further progress in the quantitative management of EVs-miRNAs would accelerate the clinical transformation of miRNAs enriched EVs in the OA field. Keywords: osteoarthritis, extracellular vesicles, microRNAs, quantitative management, clinical transformation Osteoarthritis (OA) is a common chronic inflammatory disease associated with the pathophysiological change in the whole joint tissues. 1,2 Although it is considered a senile disease previously, the incidence is increasing even among young people due to unhealthy lifestyles. 3–5 The main structural changes in the development and progress of OA are synovitis, cartilage destruction, subchondral bone sclerosis, and cyst, all of which could cause clinical symptoms from swelling and pain to joint deformity and until loss function of the joint. However, the pathological changes in cell level are still unclear, which is the main reason for the rare effective treatment to stop or reverse the progress of OA. 6 It is well known that the knee joint could synthesize and secrete extracellular matrix (ECM) mainly comprised of Collagen 2 and proteoglycan. However, the healthy knee cartilage can be affected by abnormal mechanical stress, inflammation, and metabolic disorders, further inducing abnormal expression of Collagen X, Matrix metalloproteinases (MMPs), and A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), accelerating cartilage destruction. As a result, the homeostasis of the knee joint can be reversed from anabolic towards catabolic, which cannot avoid accelerating the degradation of cartilage accompanying subchondral bone sclerosis, angiogenesis, and synovitis. 7 The leading clinical therapeutic for early-stage OA is to relieve pain, while joint replacement seems to be the only effective treatment at the end stage. 8 As a result, the number of total joint replacements has skyrocketed recently. However, this surgery also has relevant risks like postoperative anemia, infection, periprosthetic fractures, and revision surgery which is unavoided after a long period of wear and tear. 9 Hence, it is urgent to explore the pathogenesis of this disease further and find the revolutionary treatment considering the severe economic burden caused by an aging population in the following decades. MiRNAs are a group of short non-coding RNAs which could negatively regulate the target mRNAs at the posttranscriptional level and regulate gene expression in cells without modifying the gene sequence. 10 Previous studies have demonstrated that miRNAs participate in the modulation of different diseases such as cancer, cardiovascular disease, neurological disease, and also osteoarthritis. 11 Hundreds of miRNAs have shown altered expression in OA compared to healthy joint tissue, so it is promising to target specific miRNAs to interfere with -Abstract Truncated-
immunology